OTC · Drug Manufacturers - General

Mayne Pharma Group Limited (MAYNF) Stock

$1.97 +0.00% OTC: MAYNF Healthcare

Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia.

Valuation

MetricValue
Price$1.97
Market Cap$160.30M
P/E Ratio-2.55
P/B Ratio0.63
P/S Ratio0.54
EPS (TTM)$-1.14
52-Week High$4.00
52-Week Low$1.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-23.02%
ROA-8.85%
ROCE-6.65%
Gross Margin54.83%
Operating Margin-11.15%
Net Margin-20.44%
Debt/Equity0.13
Current Ratio1.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$400.0M$157.0M$184.0M$388.0M$408.0M
Operating Profit$-37.0M$-136.0M$-186.0M$-139.0M$-24.0M
Net Profit$-208.0M$-209.0M$117.0M$-174.0M$-94.0M
EPS$-2.65$-3.20$-3.67$-2.12$-1.14
Op Margin-9.1%-86.3%-101.6%-35.8%-5.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.5B$1.3B$1.2B$1.1B$1.0B
Total Liabilities$692.0M$731.0M$614.0M$689.0M$644.0M
Cash$98.0M$97.0M$102.0M$110.0M$60.0M
Borrowings$347.0M$414.0M$48.0M$70.0M$41.0M

Latest News

Marquis Who's Who Honors Shawn Patrick O'Brien for Expertise in Pharmaceuticals and Biotechnology PR Newswire · Jun 25, 2026 3 ASX Penny Stocks With Market Caps Over A$70M To Consider Simply Wall St. · May 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$47.0M$-17.0M$-43.0M$-15.0M$17.0M
Investing Cash Flow$-74.0M$-40.0M$254.0M$33.0M$-80.0M
Financing Cash Flow$-12.0M$-12.0M$-15.0M$-9.0M$3.0M
Net Cash Flow$-40.0M$-1.0M$-4.0M$17.0M$-50.0M
Free Cash Flow$22.0M$-28.0M$-263.0M$-36.0M$5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.09
EV / EBITDA8.51
FCF Yield7.09%
Quick Ratio1.14
Interest Coverage-8.83
Return 1Y-43.87%
Return 3Y-41.80%
Return 5Y-50.28%

Ownership

Insiders Held13.13%
Institutions Held36.13%
Institutions Float Held41.58%
Institutional HolderSharesReport Date
Heritage Wealth Advisors40,0002022-09-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AONCAmerican Oncology Network, Inc. $12.00 +20.00% -17.39 $350.98M 0.00%
BHCCFBenchmark Holdings plc $0.37 +0.00% -4.13 $225.11M 0.00%
BHHKFCraftport Cannabis Corp. $0.00 — 0.00 $884 0.00%
CPHRFCipher Pharmaceuticals Inc. $11.68 -0.17% 9.56 $296.57M 0.00%
EVGRFChina Evergrande New Energy Vehicle Group Limited $0.00 — -0.13 $2.17M 0.00%

About Mayne Pharma Group Limited

Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Beyond its own product lines, Mayne Pharma offers sophisticated oral drug delivery technologies and comprehensive contract services—including pharmaceutical development, manufacturing, and analytical testing—to other businesses. Its strategic focus areas for specialty product distribution include dermatology, women's health, and infectious disease treatments. Originally established in 2005, the company operated under the name Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010. Its principal office is located in Salisbury South, Australia.

Mayne Pharma Group Limited is headquartered in AU.

Mayne Pharma Group Limited (MAYNF) stock trades at $1.97 with a market capitalization of $160.30M. The stock is valued at a price-to-earnings (P/E) ratio of -2.55, price-to-book of 0.63, price-to-sales of 0.54. Over the past 52 weeks the stock has ranged between $1.40 and $4.00, and currently trades 50.8% below its 52-week high.

On profitability, Mayne Pharma Group Limited generates a return on equity (ROE) of -23.02%, return on capital employed of -6.65%, an operating margin of -11.15%, a net profit margin of -20.44%.

Official website: www.maynepharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides